drugset
drugset / Trial / NCT04367441

Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

NCT04367441 ↗

Phase 1 Unknown 62 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.

Timeline

Start
2019-11-25
Primary completion
2020-10-31
Completion
2020-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 608 Monoclonal antibody 8 mg Subcutaneous
Subject 608 Monoclonal antibody 20 mg Subcutaneous
Subject 608 Monoclonal antibody 40 mg Subcutaneous
Subject 608 Monoclonal antibody 80 mg Subcutaneous
Subject 608 Monoclonal antibody 120 mg Subcutaneous
Subject 608 Monoclonal antibody 160 mg Subcutaneous
Subject 608 Monoclonal antibody 200 mg Subcutaneous

Indications

psoriasis